Literature DB >> 12393428

Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease.

David A Weinstein1, Cindy N Roy, Mark D Fleming, Massimo F Loda, Joseph I Wolfsdorf, Nancy C Andrews.   

Abstract

The anemia of chronic disease is a prevalent, poorly understood condition that afflicts patients with a wide variety of diseases, including infections, malignancies, and rheumatologic disorders. It is characterized by a blunted erythropoietin response by erythroid precursors, decreased red blood cell survival, and a defect in iron absorption and macrophage iron retention, which interrupts iron delivery to erythroid precursor cells. We noted that patients with large hepatic adenomas had severe iron refractory anemia similar to that observed in anemia of chronic disease. This anemia resolved spontaneously after adenoma resection or liver transplantation. We investigated the role of the adenomas in the pathogenesis of the anemia and found that they produce inappropriately high levels of hepcidin mRNA. Hepcidin is a peptide hormone that has been implicated in controlling the release of iron from cells. We conclude that hepcidin plays a major, causative role in the anemia observed in our subgroup of patients with hepatic adenomas, and we speculate that it is important in the pathogenesis of the anemia of chronic disease in general.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393428     DOI: 10.1182/blood-2002-04-1260

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  150 in total

Review 1.  The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  BMPER protein is a negative regulator of hepcidin and is up-regulated in hypotransferrinemic mice.

Authors:  Neeta Patel; Patarabutr Masaratana; Javier Diaz-Castro; Gladys O Latunde-Dada; Aakafa Qureshi; Pamela Lockyer; Molly Jacob; Matthew Arno; Pavle Matak; Ragai R Mitry; Robin D Hughes; Anil Dhawan; Cam Patterson; Robert J Simpson; Andrew T McKie
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

Review 3.  Hepcidin: the missing link between hemochromatosis and infections.

Authors:  Houman Ashrafian
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

Review 4.  Hepcidin: what every gastroenterologist should know.

Authors:  A P Walker; J Partridge; S K Srai; J S Dooley
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 5.  Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.

Authors:  Chia Chi Sun; Valentina Vaja; Jodie L Babitt; Herbert Y Lin
Journal:  Am J Hematol       Date:  2012-01-31       Impact factor: 10.047

Review 6.  Iron homeostasis and the inflammatory response.

Authors:  Marianne Wessling-Resnick
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

Review 7.  Hepcidin and iron homeostasis.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Biochim Biophys Acta       Date:  2012-01-26

8.  Investigation of the role of interleukin-6 and hepcidin antimicrobial peptide in the development of anemia with age.

Authors:  Bryan J McCranor; Jacqueline M Langdon; Olivier D Prince; Laurette K Femnou; Alan E Berger; Chris Cheadle; Curt I Civin; Airie Kim; Seth Rivera; Tomas Ganz; Sophie Vaulont; Qian-Li Xue; Jeremy D Walston; Cindy N Roy
Journal:  Haematologica       Date:  2013-08-30       Impact factor: 9.941

Review 9.  Hepcidin and its role in iron absorption.

Authors:  K J Robson
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

10.  Pro-hepcidin: expression and cell specific localisation in the liver and its regulation in hereditary haemochromatosis, chronic renal insufficiency, and renal anaemia.

Authors:  H Kulaksiz; S G Gehrke; A Janetzko; D Rost; T Bruckner; B Kallinowski; W Stremmel
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.